Revue des sciences de la santé

  • ISSN: 1108-7366
  • Indice h du journal: 51
  • Note de citation du journal: 10.69
  • Facteur d’impact du journal: 9.13
Indexé dans
  • Genamics JournalSeek
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • CiteFactor
  • CINAHL complet
  • Scimago
  • Bibliothèque des revues électroniques
  • Répertoire d'indexation des revues de recherche (DRJI)
  • EMCare
  • OCLC - WorldCat
  • Commission des bourses universitaires
  • Fondation genevoise pour la formation et la recherche médicales
  • Pub européen
  • Google Scholar
  • SHERPA ROMÉO
  • Laboratoires secrets des moteurs de recherche
Partager cette page

Abstrait

Health Results and Tuberculosis Drugs in Nations with National Essential Medicines List

Robert Busen*, Frances Klsey

Tuberculosis (TB) is a major global health issue, requiring access to effective and affordable medicines for successful treatment. The presence of a National Essential Medicines List (NEML) plays a crucial role in ensuring access to TB medicines and improving health outcomes. This article examines the impact of NEMLs on TB medicines and health outcomes in countries. NEMLs enhance access to TB medicines, promote quality assurance and standardization, improve affordability, and positively influence health outcomes related to TB. The inclusion of essential TB medicines on NEMLs facilitates equitable access, reduces treatment costs, and contributes to better patient outcomes, including increased treatment success rates and reduced mortality. NEMLs are essential in the global fight against tuberculosis and should be prioritized by governments and healthcare authorities to achieve improved health outcomes and control the spread of TB.